A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the long-term safety of A-623 in subjects with SLE.

Phase 2

Anthera Pharmaceuticals